Department of Otolaryngology-Head & Neck Surgery, Beaumont Hospital, Dublin 9, Ireland; Royal College of Surgeons in Ireland, Ireland.
Department of Otolaryngology-Head & Neck Surgery, Beaumont Hospital, Dublin 9, Ireland.
Am J Otolaryngol. 2024 May-Jun;45(3):104235. doi: 10.1016/j.amjoto.2024.104235. Epub 2024 Feb 23.
The epidemiology and management of oral cavity cancer have changed considerably in recent decades. This study examines epidemiological and management trends in oral cavity squamous cell carcinoma (OCSCC).
A retrospective cohort study of data from the National Cancer Registry of Ireland between 1994 and 2014.
A total of 2725 patients were identified. The most common subsites were the tongue (34 %, n = 1025), lip (19 %, n = 575), floor of mouth (FOM) (18 %, n = 550), and retromolar trigone (RMT) (6 %, n = 189). The incidence of OCSCC remained largely unchanged (3.14 cases/100000/year) during the study period. 5-year disease-specific survival (DSS) was 58.6 % overall, varying between subsites (lip 85 %, RMT 62.9 %, tongue 54.7 %, and FOM 47.3 %). DSS improved over the study period (p = 0.03), in particular for tongue primaries (p = 0.007). Primary surgery significantly improved DSS versus radiotherapy (HR 0.28, p < 0.0001). Survival of T4 disease managed surgically was superior to that of T1 disease managed with radiotherapy. In node positive patients, chemotherapy improved overall survival (HR 0.8 p = 0.038) but not DSS (HR 0.87 p = 0.215).
Primary surgery remains the standard of care in the management of OCSCC. Prognosis has improved in line with an increase in the use of primary surgery in the same time frame, though the incidence remains unchanged.
近年来,口腔癌的流行病学和治疗方法发生了很大变化。本研究旨在探讨口腔鳞状细胞癌(OCSCC)的流行病学和治疗趋势。
对爱尔兰国家癌症登记处 1994 年至 2014 年期间的数据进行回顾性队列研究。
共确定了 2725 例患者。最常见的部位是舌(34%,n=1025)、唇(19%,n=575)、口底(FOM)(18%,n=550)和磨牙后三角(RMT)(6%,n=189)。在研究期间,OCSCC 的发病率基本保持不变(3.14 例/100000/年)。总体 5 年疾病特异性生存率(DSS)为 58.6%,不同部位之间存在差异(唇 85%、RMT 62.9%、舌 54.7%和 FOM 47.3%)。DSS 在研究期间有所提高(p=0.03),尤其是舌癌(p=0.007)。与放疗相比,原发手术显著提高了 DSS(HR 0.28,p<0.0001)。手术治疗 T4 期疾病的生存优于放疗治疗 T1 期疾病。在淋巴结阳性患者中,化疗改善了总生存率(HR 0.8,p=0.038),但未改善 DSS(HR 0.87,p=0.215)。
原发手术仍是 OCSCC 治疗的标准。尽管发病率保持不变,但随着同一时期原发手术应用的增加,预后有所改善。